Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors

Article abstract of DOI:10.1016/j.bmc.2015.08.010

The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the thioether, showed the lowest IC₅₀ values in enzymatic assays (10-206 nM), the most potent compounds 4d-4h (IC₅₀ 10-28 nM) bearing hydrophobic groups (Me, F, CF₃ and Cl) in the terminal phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentrations. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited at 1.0 and 2.5 μM for the most promising compounds. Altogether, these findings point to an antiangiogenic effect in HUVECs.

Full text of DOI:10.1016/j.bmc.2015.08.010

Accepted Manuscript
Synthesis, Antiangiogenesis Evaluation and Molecular Docking Studies of 1-
Aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a New Sub-
stitution Pattern for type II VEGFR-2 Tyr Kinase Inhibitors
Vera A. Machado, Daniela Peixoto, Raquel Costa, Hugo J.C. Froufe, Ricardo
C. Calhelha, Rui M.V. Abreu, Isabel C.F.R. Ferreira, Raquel Soares, Maria-
João R.P. Queiroz
PII:
S0968-0896(15)00677-X
http://dx.doi.org/10.1016/j.bmc.2015.08.010
BMC 12514
DOI:
Reference:
To appear in:
Bioorganic & Medicinal Chemistry
Received Date:
Revised Date:
Accepted Date:
11 June 2015
1 August 2015
12 August 2015
Please cite this article as: Machado, V.A., Peixoto, D., Costa, R., Froufe, H.J.C., Calhelha, R.C., Abreu, R.M.V.,
Ferreira, I.C.F., Soares, R., Queiroz, M.R.P., Synthesis, Antiangiogenesis Evaluation and Molecular Docking
Studies of 1-Aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a New Substitution Pattern for type
II VEGFR-2 Tyr Kinase Inhibitors, Bioorganic & Medicinal Chemistry (2015), doi: http://dx.doi.org/10.1016/j.bmc.
2
015.08.010
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Synthesis, Antiangiogenesis Evaluation and Molecular Docking Studies of 1-
Aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a New
Substitution Pattern for type II VEGFR-2 Tyr Kinase Inhibitors
a,b
a
b
c
a,c
Vera A. Machado , Daniela Peixoto , Raquel Costa , Hugo J.C. Froufe , Ricardo C. Calhelha , Rui
c
c
b
a
M.V. Abreu , Isabel C.F.R. Ferreira , Raquel Soares , Maria-João R. P. Queiroz, *
a
Departamento/Centro de Química, Escola de Ciências, Universidade do Minho, Campus de
Gualtar 4710-057 Braga, Portugal
b
Departamento de Bioquímica, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto,
Portugal; I3S – Instituto de Investigação e Inovação em Saúde, Porto, Portugal
c
CIMO-ESA, Instituto Politécnico de Bragança, Campus de Sta. Apolónia, Apartado 1172, 5301-855
Bragança, Portugal
*Corresponding author: E-mail address: mjrpq@quimica.uminho.pt (M.-J.R.P. Queiroz) Tel.:
+351-253604378
1

Abstract
The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-
ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-
(
thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the
thioether, showed the lowest IC50 values in enzymatic assays (10-206 nM), the most potent
compounds 4d-4h (IC50 10-28 nM) bearing hydrophobic groups (Me, F, CF and Cl) in the terminal
3
phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type
II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the
arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical
Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and
tube formation were observed at low concentrations. These compounds have also shown to increase
apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2
was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited
at 1.0 and 2.5 mM for the most promising compounds. Altogether, these findings point to an
antiangiogenic effect in HUVECs.
Keywords: Thienopyridinethioether 1,3-diarylureas; VEGFR-2 tyrosine kinase inhibitors; Enzymatic
assays; Molecular Docking; HUVECs; Antiangiogenesis assays, Western blotting
2

1. Introduction
The Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) is a class V Receptor Tyrosine
Kinase (RTK), expressed primarily in endothelial cells, and is activated by the specific binding of
Vascular Endothelial Growth Factor (VEGF), secreted by endothelial cells and various tumor cells,
to the VEGFR-2 extracellular regulatory domain. Once activated, VEGFR-2 undergoes
autophosphorylation, triggering signalling pathways leading to endothelial cell proliferation and
1
subsequent tumor angiogenesis that promotes tumor growth and metastasis. Several small-molecule
VEGFR-2 inhibitors have emerged as promising antiangiogenic agents for treatment against a wide
variety of cancers and act by competing with adenosine triphosphate (ATP) for the ATP-binding site
of the VEGFR-2 intracellular kinase domain, thereby preventing the intracellular signalling. This
2
leads to angiogenesis, the sprouting of new capillaries from pre-existing blood vessels, which is a
multistep process involving endothelial cell differentiation, proliferation, migration, permeability
3
and tube formation. These assays are used to reproduce the angiogenesis process in vitro.
Most known kinase inhibitors are classified as type I kinase inhibitors, which bind in and around the
4
region occupied by the adenine ring of ATP. Sunitinib is a classical example of a type I inhibitor and
5
has been approved for the treatment of renal cell carcinomas and gastrointestinal stromal tumors.
On the other hand, type II kinase inhibitors induce the inactive DFG-out conformation of the
activation loop, enabling them to occupy the adenine binding site and an adjacent hydrophobic
pocket created by this rearrangement. As the residues forming the hydrophobic pocket are less
conserved than residues in the adenine pocket, type II inhibitors usually provide a better kinase
4
, 6
selectivity when compared to type I inhibitors.
For VEGFR-2, several type II inhibitors have been reported. These inhibitors occupy the adenine
pocket with a suitable ring or ring system that is able to promote 1 to 3 H-bonds with the kinase
hinge region (Glu917-Cys919); while also occupying the hydrophobic pocket that is available in the
3

DFG-out conformation (Asp1046-Phe1047-Gly1048 for VEGFR-2), with a suitable ring or ring
system. A pair of hydrogen bond donating and accepting groups, (usually an urea or a corresponding
bioisosteric core) is also present to establish H-bonds with Asp1046 and Glu885. The ring systems
occupying both the adenine and the hydrophobic pocket are usually linked via a central ring
positioned in an intermediate linker region (Figure 1 and 2).
A number of type II VEGFR-2 inhibitors, relevant for the discussion of the results are presented in
figure 1. They present a typical pharmacophore model for these inhibitors where a central aryl ring,
occupying the linker region, is bound to the ring occupying the adenine pocket via an ether linker
(
O-linker), while the ring in the hydrophobic pocket is bound to the central ring via an urea group in
para position to the O-linker. In the course of molecular modelling studies performed in our group
and following a previous study presenting thieno[3,2-d]pyrimidines as VEGFR-2 inhibitors, several
observations suggested that alternatives to the O-linker using different configuration patterns, could
1
0
be explored in an attempt to synthesize original VEGFR-2 inhibitors. Specifically the use of a
thioether linker (S-linker) instead of an ether linker (O-linker) could provide interesting compounds
with potent VEGFR-2 inhibition capability and with an alternative profile to the existent type II
VEGFR-2 inhibitor scaffolds. Sorafenib was used for comparison with compounds that present
similar substituents in the terminal aryl ring located in the hydrophobic pocket.
4

Adenine
Pocket
Hydrophobic
Pocket
Linker
region
H
H
N
N
N
H
N
O
O
Cl
O
Sorafenib
CF3
F
H
N
H
N
N
HN
O
O
O
N
O
H
A
CF3
F
H
H
N
N
N
N
O
O
N
CF3
B
Figure 1. VEGFR-2 type II inhibitors presenting an O-linker in the para position relative to the urea
7
8
moiety: Sorafenib (Nexavar®, Bayer, Germany; IC50 = 90 nM), A (TSK/Tsukuba IC50 = 3.5 nM)
9
and B (pyrrolo[3,2-d]pyrimidine derivative; IC50 = 6.2 nM).
Herein, we describe an on-going effort to develop novel small-molecule VEGFR-2 inhibitors, based
on the thieno[3,2-b]pyridine-7-thioether-1,3-diarylurea scaffold. The synthesis and the VEGFR-2
enzymatic inhibition activity assays of a novel series of 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-
ylthio)phenyl]ureas are presented. Docking simulations were performed to analyze the binding mode
of the more potent synthetized compounds. The best compounds identified in enzymatic assays were
then tested in VEGF-stimulated Human Umbilical Vein Endothelial Cells (HUVECs). Their
proliferation, apoptosis, migration and tube formation, VEGFR-2 expression and activity were
examined by BrdU, TUNEL, wound healing and matrigel assays, and by Western blot, respectively.
5

2. Results and Discussion
2
.1. Synthesis
1
1a,b
The 7-chlorothieno[3,2-b]pyridine 1,
b]pyridine and POCl , reacted with 2- 3- or 4-aminothiophenol in stoichiometric amounts in DMF at
40 ºC for 2h to give only the aminated di(hetero)arylthioethers 2a-c by nucleophilic aromatic
substitution, in very good yields (Scheme 1). These were reacted with differently substituted
arylisocyanates in THF/CH Cl at room temperature for 12 h, to give the 1-aryl-3-[2-, 3- or 4-
thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3a-c, 4a-h and 5a-e in good yields (Scheme 1). The
obtained from the commercial 7-hydroxythieno[3,2-
3
1
2
2
(
synthesis of compounds 4d-h bearing hydrophobic groups, was performed after the best results
obtained in enzymatic assays (Table 1) for the substitution pattern of compounds 4a-4c. For the
compounds 5, based also in the results of enzymatic assays (Table 1) that were not so good then for
series 4, only compounds with substituents that are present in Sorafenib (Figure 1) CF and/or Cl,
3
were prepared in order to evaluate their effects.
N
S
N
N
S
n
C
R = H unless stated
O
S
R1
1
S
3
a R =H, 65%
R1
1
3b R =OMe, 63%
O
1
HS
H N
3c R =CN, 65%
ii)
N
H N
2
N
N
H
2
a, 80%
H
2
R2
i)
4'''
C
NH2
4'
N
3'''
4a R =H, 63%
1
O
3
'
5'''
6'''
N
5
'
R1
2'''
S1'''
1
4b R =OMe, 64%
2
'
HS
HS
1
N
4c R =CN, 65%
7
'''
S
i)
6'
S
2
H 2 H
1
'
2''
1'
2'
R2
3'
1
7
'
1'' N
N
1
4d R =F, 71%
ii)
S
3
NH2
3
2
S
4
e R =F, 69%
1
3''
5''
O
6'
4' R1 4f R =Me, 72%
2
Cl
NH2
4
6
4''
5'
2
5
4g R =CF , 50%
1
3
1
2
2
b, 90%
4h R =Cl,R =CF , 60%
3
i)
N
N
N
S
C
O
S
1
R1
S
R2
5a R =H, 65%
S
1
R1
5b R =OMe, 70%
5
i) K CO (4 equiv.), DMF, 140ºC, 2h
2
3
ii)
O
1
c R =CN, 65%
ii) arylisocyanates (1 equiv.),
CH Cl : THF (1:1), rt, 12h
2
NH2
5d R =CF , 55%
2
2
3
N
N
1
2
2
c, 90%
H
H
5e R =Cl, R =CF , 72%
3
6

Scheme 1. Synthesis of the 2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)anilines 2a-c and of the 1-aryl-
3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3-5.
2
.2. Enzymatic Inhibition and Structure Activity-Relationship
Compounds 3a-c, 4a-c and 5a-c were first synthetized and subsequently evaluated for their ability to
1
2
interact with the VEGFR-2 kinase domain (Table 1), using an enzymatic FRET-based assay. The
three series differ in the position of the arylurea scaffold; with compounds 3, 4 and 5 bearing it in
the ortho, meta and para-position relative to the thioether linker, respectively. Compounds 4a-c
displayed the highest enzyme inhibition potency with IC50 values of 94, 107 and 206 nM,
respectively; whereas compounds 5a , 5b displayed either moderate, 1160 and 1390 nM,
respectively, or 5c weak VEGFR-2 inhibition activity, 8360 nM; compounds 3a-c were inactive.
These findings are surprising as compounds 5 present similarities with known VEGFR-2 inhibitors
8
-10, 13-15
7
with the arylurea moiety in the para position,
including the drug Sorafenib (Figure 1).
Instead, compounds 4a-4c with the arylurea group in the meta position, were an order of magnitude
more potent. The arylurea in the meta position is usually not considered as a promising feature and
the studies using different scaffolds as potential VEGFR-2 inhibitors always explore the arylurea in
7
-10, 13-15
the para position
although presenting an O-linker instead of a S-linker.
In fact, considering the number of scaffolds with VEGFR-2 inhibitory activity already published, it
is surprising that a S-linker in meta position relative to the urea moiety was not explored before by
others. The explanation is probably inherent to the rational of the drug design process where only
8
one feature is explored at a time. We have found at least two studies performed by Hasegawa et al.
9
and Oguro et al. where the importance of the O/S linker atom and the meta/para position relative to
the urea moiety was analyzed in a series of benzimidazole and pyrrolo[3,2-d]pyrimidine derivatives,
7

respectively. These compounds explore the same VEGFR-2 binding mode with the best clinical
candidate provided by each study presented as compound A (benzimidazole) and B (pyrrolo[3,2-
d]pyrimidine derivative) (Figure 1). In both studies the O/S-linker was investigated only in para
position relative to the urea moiety, with the S-linker always providing less potent compounds and
being discarded for further synthesis. In fact the presence of a S-linker, when compared to similar
compounds with an O-linker, lowered the VEGFR-2 inhibition potency by 3-fold and 20-fold for the
benzimidazole and pyrrolo[3,2-d]pyrimidine derivatives, respectively. Similarly, the meta/para
position relative to the urea was only investigated using an O-linker, with the meta position always
providing less potent compounds and thus also being discarded for further synthesis. Also
compounds with the O-linker and urea in the meta position lowered the activity by 6-fold and 55-
fold for the benzimidazole and pyrrolo[3,2-d]pyrimidine derivatives, respectively, when compared to
compounds with the O-linker in the para position relative to the urea. As far as our knowledge, this
thieno[3,2-b]pyridine series is the first that presents compounds with a S-linker in the meta position
relative to the urea moiety with potent inhibition activity against VEGFR-2. This study provides a
new insight in the field as this substitution pattern was not previously investigated and has been
thought to be of low potency.
Typically, for type II VEGFR-2 inhibitors, the terminal aryl ring that occupies the hydrophobic
pocket is functionalized with hydrophobic substituent groups, the most frequent being methyl
groups or halogen atoms in meta or para position, although other substitution pattern is observed
(
Figure 1). Based on this information compounds 4d-h were synthetized in an attempt to obtain
more potent VEGFR-2 inhibitors than compounds 4a-4c. Compounds 4d with a F atom in the para
position or 4e with a F in the meta position, 4f with a methyl group, 4g with a CF both in the meta
position and 4h with a CF in meta and a Cl in the para position, relative to the urea moiety, were
3
3
the most potent VEGFR-2 inhibitors in enzymatic assays with IC50 values of 10, 28, 11, 15 and 16
8

nM, respectively (Table 1). These values are in line with the most potent VEGFR-2 inhibitor agents
and pending further analysis, but compounds 4d-h can already be considered as potential leads as
antiangiogenic compounds. This increase of potency in one order of magnitude with hydrophobic
substituents in the terminal aryl ring provides evidence that the latter in fact occupies the
hydrophobic pocket in a similar fashion to other known type II inhibitors.
Although compounds 5 have given high IC50 values it was decided to prepare compounds in this
series with substituents CF
3
and/or Cl present in the Sorafenib, but the IC50 values did not
significantly decreased (Table 1).
Table 1. VEGFR-2 inhibition activity of compounds 3a-c, 4a-h and 5a-e
a
VEGFR-2; IC50
Compound
(
using 10 µM of ATP)
>100000 nM
>100000 nM
>100000 nM
94 nM
3a
3b
3c
4a
4b
107 nM
4c
206 nM
4d
10 nM
4e
28 nM
4f
11 nM
4g
15 nM
4h
16 nM
5
a
1160 nM
1390 nM
8360 nM
988 nM
5b
5
c
5d
5
e
1947 nM
6 nM
b
Staurosporine
9

(enzymatic kit
control)
a
Each IC50 determination is a result of at least four separate determinations.
b
16
Staurosporine experimental VEGFR-2 IC50 = 7 nM.
In order to explain the VEGFR-2 inhibitory activity of compounds 4, we set out to investigate in
detail the binding mode of compounds 4d and 4f and 5a by performing molecular docking studies.
2
.3. Molecular Docking Simulations
To better understand the structural rational behind the VEGFR-2 inhibition potency observed for the
synthesized compounds, molecular docking simulations were performed using AutoDock4 software.
The VEGFR-2 kinase domain crystal structure with PDB code: 3VHE was selected because it
presented a co-crystallized inhibitor (compound B, Figure 1) with the closest structure compared to
the compounds prepared in this work. For a suitable comparison, compounds 5a and compounds 4d
and 4f were docked against the selected structure and then superimposed with the experimental
structure of compound B (Figure 2A and 2B). The other compounds of series 5 were also docked
and the obtained docking poses were a near perfect superimposition of compound 5a docking pose.
So for clearance of representation on figure 2A only compound 5a was used as it is the simplest,
without substitution in the terminal aryl ring.
For the less potent compound 5a a similar binding mode pattern to compound B was observed
(
Figure 2A). In both compounds the urea moiety forms two H-bonds with the Glu885 carboxyl
group, and the C=O urea group forms a third H-bond with the backbone N–H of Asp1046. The
thieno[3,2-b]pyridine moiety is docked in adenine pocket with a near perfect superimposition to the
pyrrolo[3,2-d]pyrimidine ring of compound B, and both rings are positioned in order to form the
critical H-bond with the Cys919 backbone N-H group. The central aryl group is docked on the linker
region and the terminal aryl ring on the hydrophobic pocket (Figure 2A). However a more detailed
10

inspection of compound 5a docking pose gives us some insights on why the S-linker in the para
position is probably less favored compared to the O-linker in the same position. In fact, in order to
accommodate the network of critical H-bonds and allow a correct pocket occupation of the ring
o
systems, the S-linker was stretched to a 109.5 angle when the more stable value for a S-linker angle
is approximately 90º (Figure 2A). The co-crystallized structure of compound B on the other hand
1
7
presents a O-linker angle of 115.8º that is closer to the ideal 110º angle. This widening of the S-
linker is energetically unfavorable and probably explain the much lower potency of compound 5a
(
IC50 = 1166 nM) compared to compound B (IC50 = 6.2 nM). It is likely that there may be a protein
shifting in the active site to relieve this very high energy situation and the docking presented in
Figure 2A is likely to be an approximation of the actual interaction between compound 5a and the
active site.
For the most potent compounds 4d and 4f (IC50 of 10 and 11 nM, respectively) the same
superimposition with compound B is also presented (figure 2B). A closer inspection of the docked
poses shows that, due to the presence of the S-linker in the meta position relative to the urea group,
the central aryl ring is placed deeper inside the linker region, when compared to compound B. The
S-linker sharper angle (100.4º) is close to the ideal 90º angle and now appears to work in favor of
increasing VEGFR-2 inhibitory potency by enabling a more favored occupation of the linker region
by the central aryl ring. In fact this ring is superimposed with the F atom of compound B, further
evidence that this linker region occupation pattern is possible and probably favored.
The higher inhibition potency of compound 4d with an F atom in the para position and 4f with a
methyl group in the meta position, relative to the urea moiety, when compared to compound 4a with
no substitution, is also widely observed for other known type II inhibitors (Figure 1) and it is due to
1
3-15
a better occupation of the hydrophobic pocket.
predicted docked poses are probably correct.
This observation further demonstrates that the
11

Figure 2. Docking pose superimposition of: (A) compound 5a (green) and (B) compounds 4d and 4f
green), with the co-crystallized structure of compound B (cyan). A partial surface representation of
(
the VEGFR-2 kinase binding site is depicted with the relevant residues presented (white). H-bonds
are represented in dashed red lines (distances between 2.8 and 3.4 Å). Structures were prepared
1
8
using PyMOL.
12

2.4. Cell Culture Assays
The best compounds in enzymatic assays (4a-h) against VEGFR-2 tyrosine kinase domain were
examined in cell culture viability and proliferation assays using HUVECs stimulated by VEGF. Cell
viability was first analyzed by MTS assay (Figure 3). The effects of compounds 4a-f at 0.1 to 10 µM
on HUVECs viability are shown in Figure 3A. Cell viability was reduced by each compound at a
dose-dependent manner, reaching statistical significance at the concentration of 5.0 µM or higher.
The effects of compounds 4g and 4h on HUVECs viability were analyzed. Given the similarity of
the hydrophobic chemical pattern substitution of Sorafenib, this drug was used as a positive control
for compounds 4g and 4h, these two compounds being used at 1.0 to 10 µM, the concentrations
established for Sorafenib in cell culture assays (Figure 3B). Compound 4g significantly reduced the
cell viability at 10 µM, while compound 4h did it at 2.5, 5.0 and 10 µM. Nevertheless, they only
affected more than 50% cell viability (4g = 44%, 4h = 26%), revealing a cytotoxic effect on
HUVECs for the highest concentration tested (10 µM), as Sorafenib (18%). Altogether, these
findings reveal that every compound was able to decrease HUVECs viability. Though, compounds
4g and 4h presented significant reductions at lower concentrations.
13

Figure 3. Evaluation of the HUVECs viability effects of compounds 4a-h and Sorafenib on VEGF-
stimulated HUVECs by MTS assay. (A) HUVECs viability upon treatment with compounds 4a-f at
concentrations of 0.1 to 10 µM. (B) HUVECs viability upon treatment with compounds 4g, 4h and
Sorafenib at 1.0 to 10 µM. Results were obtained after 24 h, and are expressed as percentage of
control (0.1% DMSO with 60 ng/mL VEGF) as means ± SEM of at least three independent
*
experiments, performed in triplicate. p < 0.05 versus control.
A proliferation assay was then assessed using the BrdU incorporation, a thymidine analogue which
1
1
incorporates into DNA of dividing cells (Figure 4). Compounds 4a (R = H), 4c (R = CN), and 4f
2
(
R = Me) showed a statistical significant antiproliferative effect at 1.0 µM (Figure 4A) without
1
1
significantly affecting cell viability (Figure 3A). Remarkably, compounds 4b (R = OMe), 4d (R =
2
F) and 4e (R = F) showed a higher antiproliferative effect, revealing a statistical significant cell
proliferation decrease at 0.5 µM (Figure 4A) without affecting cell viability (Figure 3A).
2
1
2
Compounds 4g (R = CF
3
), 4h (R = Cl; R = CF ) significantly inhibited proliferation of HUVECs
3
14

at 2.5 and 5.0 µM, without high cytotoxic effect. Sorafenib is known to prevent cell growth in
7
endothelial cells. Interestingly enough, compounds 4g and 4h exhibit, thus, a more noteworthy
effect than Sorafenib, which only significantly affected proliferation of these cells at 5.0 mM (Figure
4
B).
These results showed that all the tested compounds considerably inhibit VEGF-stimulated HUVECs
proliferation in a dose-dependent manner at low concentrations.
Figure 4. Effect of compounds 4a-4h and Sorafenib on VEGF-induced HUVECs proliferation
assessed by BrdU incorporation assay. (A) HUVECs proliferation upon treatment with compounds
4
a-4f at concentrations of 0.1 to 10 µM. (B) HUVECs proliferation upon treatment with compounds
g, 4h and Sorafenib at concentrations of 1.0 to 10 µM. Results were obtained after 24 h incubation,
4
and are expressed as percentage of control (0.1% DMSO with 60ng/mL VEGF) as means ± SEM of
*
at least three independent experiments, performed in triplicate. p < 0.05 versus control.
15

2.5. Effect on Apoptosis
The induction of apoptosis is a therapeutic approach for cancer treatment. Several anticancer drugs,
1
9
including some VEGFR-2 inhibitors can promote apoptosis. The effect of compounds 4a-h on cell
apoptosis was then evaluated by TUNEL assay (Figure 5). Concentrations of 0.1 to 1.0 µM of
compounds 4a-4f were used in the subsequent assays due to their antiproliferative effect without
cytotoxic effect at these concentrations (Figure 5A). An increase in apoptosis was observed when
HUVECs were incubated with increasing concentrations of the tested compounds for 24 h, reaching
statistical significance only for 4b-4d at the highest concentration tested (1.0 µM) in comparison to
control. These findings indicate that besides the effects of these three compounds in HUVECs
proliferation, they also induce apoptosis. Compounds 4a, 4e and 4f increased apoptosis in a dose-
dependent manner, but not with statistical significance (Figure 5A).
For compounds 4g and 4h, the concentrations selected for this and the following assays were 2.5 and
5
.0 µM since they are the lowest concentrations of these compounds that have shown an
antiproliferative effect without being cytotoxic to HUVECs (Figure 3B and 4B). As shown in Figure
B, 4g and 4h significantly increase apoptosis at 5.0 µM. Many studies report that Sorafenib induces
5
1
9
apoptosis. The findings in this study reveal that compounds 4g and 4h exhibited a higher effect
than Sorafenib in apoptosis.
16

Figure 5. Effect of compounds 4a-4h and Sorafenib on apoptosis assessed by TUNEL assay. (A)
HUVEC apoptosis upon treatment with compounds 4a-4f at concentrations of 0.1 to 1.0 µM. (B)
HUVEC apoptosis upon treatment with compounds 4g, 4h and Sorafenib at concentrations of 2.5
and 5.0 µM. Bars represent the percentage of apoptotic cells evaluated by ratio between TUNEL-
stained cells and DAPI-stained nuclei in every culture. Results were obtained after 24 h, and are
*
expressed as mean ± SEM of at least three independent experiments. p < 0.05 versus control.
2.6. Effect on HUVECs migration
2
0
Cell migration is an essential feature for endothelial cells in angiogenesis. Therefore, we next
examined the effect on the HUVECs chemotactic motility of the most promising compounds 4d-4h,
according to the previous results on HUVECs viability and proliferation, by wound-healing assay
(
Figure 6). The results show that compounds 4d-4f significantly inhibited VEGF-induced HUVECs
17

migration in a dose-dependent manner ranging from 0.1 µM to 5.0 µM (Figure 6A). Treatment with
compounds 4g and 4h significantly inhibited HUVECs migration at concentrations of 2.5 µM and
5.0 µM showing a similar effect to Sorafenib (Figure 6B). These findings regarding Sorafenib effect
2
1
in endothelial cell migration were corroborated by previous studies in the literature. Nonetheless,
incubation with compound 4h was more effective than Sorafenib, implying a better inhibitory role in
this relevant angiogenic step.
Figure 6. Effect of compounds 4d-4h on HUVECs migration (wound-healing assay) after
incubation during 24 h. Representative fields were photographed, 100´ magnification. The graphics
shows the quantitative effect of compounds 4d-4f (A), 4g-4h and Sorafenib (B) on VEGF-induced
HUVECs motility. Data presented the percentage of control, as mean ± SEM of three independent
18

*
experiments. p < 0.001 versus control.
2.7. Effect on HUVECs tube formation
To elucidate the possible mechanisms of angiogenesis inhibition, tube formation ability of
endothelial cells, which is also a critical step in the angiogenic process, was assessed in HUVECs.
As shown in Figure 7, HUVECs plated on a Matrigel coated plate formed capillary-like structures in
cells cultured in the absence of compounds (control). A significant decrease of these structures was
observed whenever cells were incubated with compounds 4d-4f at concentrations of 0.5 to 5.0 µM,
in a dose-dependent manner (Figure 7A). In the presence of compounds 4g, 4h or Sorafenib at
concentrations of 2.5 and 5 µM, tube formation of HUVECs was significantly reduced (Figure 7B),
except for 4g at 2.5 µM. This assay is a hallmark of angiogenesis evaluation in vitro. Interestingly,
prevention of this process was also accomplished by every compound tested in the present study in a
significant manner, implying thus, the important antiangiogenic role of these molecules.
19

Figure 7. Effect of compounds 4d-4h on VEGF-induced capillary-like tube formation of HUVEC
through Matrigel in 24 h. Representative fields were photographed, 100´ magnification. Bars show
the quantitative effect of compounds 4d-4f (A), 4g-4h and Sorafenib (B) on VEGF-induced HUVEC
tube formation. Data were presented as the percentage of control, as mean ± SEM of three
*
independent experiments. p < 0.001 versus control.
2.8. Effect on VEGFR-2 phosphorylation
The results presented herein were obtained in VEGF stimulated HUVECs cultures, implying that the
compounds analyzed were able to exert their effects by interfering with VEGF signalling pathway.
To confirm this hypothesis, a Western blotting assay for total and phosphorylated (active) VEGFR-2
was performed. At 1.0 µM compounds 4a, 4b and 4d-4f significantly decreased the active form of
VEGFR-2 (Figure 8A-D) (*p<0.05 vs. control). Moreover, compounds 4g and 4h, at concentrations
of 2.5 and 5.0 µM, significantly decreased VEGFR-2 phosphorylation, presenting a better effect than
Sorafenib (Figure 8E and F).
VEGF signalling pathway through the VEGFR-2 tyrosine kinase phosphorylation displays a crucial
2
2
role in angiogenesis, namely, enhancing endothelial cell survival, proliferation and migration.
Many other signalling pathways are involved in angiogenesis, nevertheless, VEGF signalling, an
angiogenic surrogate pathway, which is involved in the whole multistep process, from cell
proliferation, migration, invasiveness capacity, anastomosis, ending up in the assembly of newly
formed vascular structures. Therefore, we believe that inhibiting this pathway is an effective
approach against angiogenesis.
20

Figure 8: (A, C and E) Evaluation of phosphorylated and total VEGFR-2 expression in HUVECs
after incubation with compounds 4a-4h, by Western blotting. Representative bands obtained after
immunostaining are shown. (B, D and F) Quantification by densitometry and mean relative intensity
by comparison of the relative intensity of activated VEGFR-2 after normalization with total
*
VEGFR-2 intensity. Data presented as mean ± SEM of two independent experiments. p < 0.05
versus control.
21

3
. Conclusion
In conclusion the synthesis of new 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas
, 4 and 5 in overall good yields is reported. Compounds 4, with the arylurea in the meta position
3
relative to the S-linker, showed to be the most potent phosphorylation tyrosine kinase VEGFR-2
inhibitors, presenting IC50 values between 10-206 µM in enzymatic assays, depending on the
substituents on the terminal phenyl ring. To better understand these results, molecular docking
simulations were performed. The predicted docked poses were analyzed in detail and a plausible
explanation for compounds 4 and in particularly for 4d and 4f potency (10 and 11 nM) was obtained
based on the simultaneous presence of a S-linker and the arylurea moiety in the meta position as a
new substitution pattern for the type II VEGFR-2 inhibitors. The importance of hydrofobic
substituents in 4d and 4f (F and Me, respectively) in the terminal phenyl ring is also highlighted.
These chemical features place the thieno[3,2-b]pyridine and the terminal aryl ring in close
superimposition to a pyrrolo[3,2-d]pyrimidine derivative, type II co-crystallized VEGFR-2 ligand.
Compounds 4g an 4h with pattern substitution closer to Sorafenib showed also low IC50 values (15
and 16 nM).
Our results showed that compounds 4 affect various steps of angiogenesis including endothelial cell
proliferation, apoptosis, migration and capillary structure formation in a dose dependent manner.
In the present study we found that compounds 4 significantly block the tyrosine kinase
phosphorylation of VEGFR-2, as observed by Western blotting in vitro, suggesting these compounds
as potent VEGFR-2 inhibitors.
As far as our knowledge the S-linker in the meta position relative to the urea moiety constitutes a
new substitution pattern that has not been disclosed in other known type II VEGFR-2 inhibitors.
This can thus be regarded as an interesting feature for the synthesis of new compounds with higher
VEGFR-2 inhibitory activity and also for other scaffolds exploring the same VEGFR-2 binding
22

conformation.
Although future studies, namely using animal models, are crucial, overall, our findings support the
hypothesis that all these molecules are potent antiangiogenic agents.
4. Experimental Section
4
.1. Synthesis
o
1
13
Melting points ( C) were determined in a Stuart SMP3 and are uncorrected. H and C NMR spectra
were recorded on a Varian Unity Plus at 300 and 75.4 MHz, respectively or on a Bruker Avance III
at 400 and 100.6 MHz, respectively, and the chemical shifts were quoted in parts per million (ppm)
referenced to the appropriate non-deuterated solvent peak relative to 0.0 ppm for tetramethylsilane.
1
13
Two dimensional H- C correlations were performed to attribute some signals. Mass spectra (MS)
+
+
EI -TOF or ESI-TOF and HRMS on the M or on the [M+H] were performed by the mass
spectrometry service of the University of Vigo, C.A.C.T.I., Spain and the low resolution MS ESI of
compounds 4g, 4h, 5d and 5e were performed by direct injection on a ThermoFinigan
spectrophotometer LC-MS. Elemental Analysis was performed on a LECO CHNS 932 Elemental
Analyser. The compounds yielded data consistent with a purity of at least 95% as compared with the
theoretical values. The reactions were monitored by thin layer chromatography (TLC) using
Macherey-Nagel pre-coated aluminium silica gel 60 sheets (0.20 mm) with UV254 indicator.
Column chromatography was performed on Panreac, Silica Gel 60, 230-400 mesh. Ether refers to
o
diethylether. Petroleum ether refers to the boiling range 40-60 C. Aminothiophenols were purchased
from Sigma-Aldrich with purity ≥ 96%.
4.1.1. General synthesis procedure for compounds 2a-c: In a flask with DMF (5 mL), compound 1,
23

the aminothiophenol (1equiv.) and K
water (5 mL) and ethyl acetate (5 mL) were added. The phases were separated and the aqueous
phase was extracted with more ethyl acetate (2x5mL). The organic phase was dried (MgSO ) and
2
CO
3
(4equiv.) were heated at 140 ºC for 2h. After cooling
4
filtered. The solvent was evaporated under reduced pressure giving an oil which was submitted to
column chromatography.
4.1.1.1. 2-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2a): Compound 1 (150 mg, 0.880 mmol) and 2-
aminothiophenol (110 mg) and the general procedure was followed. Column chromatography using
1
7
0% ether/petroleum ether gave compound 2a as an oil (180 mg, 80%). H NMR (DMSO-d
6
, 300
MHz): δ 5.54 (br s, 2H, NH
2
), 6.57 (d, J = 5.2 Hz, 1H, 6’-H), 6.62-6.67 (m, 1H, 4-H), 6.87 (dd, J =
8.4 and 1.5 Hz, 1H, 6-H), 7.25-7.30 (m, 1H, 5-H), 7.37 (dd, J = 8.4 and 1.5 Hz, 1H, 3-H), 7.57 (d, J
1
3
=
5.6 Hz, 1H, HetArH), 8.14 (d, J = 5.6 Hz, 1H, HetArH), 8.42 (d, J = 5.2 Hz, 1H, 5’-H) ppm. C
NMR (DMSO-d6, 75.4 MHz,): δ 107.2 (C), 114.0 (6’-CH), 115.3 (6-CH), 116.9 (4-CH), 124.9 (CH),
29.3 (C), 131.6 (CH), 132.3 (5-CH), 137.4 (3-CH), 142.5 (C), 147.2 (5’-CH), 151.1 (C), 155.7 (C)
1
+
+
ppm. MS (EI- TOF) m/z (%): 258.03 (M , 100). HRMS (EI-TOF): calcd for C13
H
10
N
2
S [M ]
2
258.0285, found 258.0284.
4.1.1.2. 3-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2b): Compound 1 (200 mg, 1.20 mmol) and 3-
aminothiophenol (125 mg) and the general procedure was followed. Column chromatography using
1
4
5% ether/petroleum ether gave compound 2b as a yellow solid (280 mg, 90%). Mp 106-107 ºC. H
NMR (DMSO-d
6
, 400 MHz): δ 5.40 (br s, 2H, NH
2
), 6.69-6.71 (m, 2H, 4 and 6-H), 6.75-6.76 (m,
1
1
H, 2-H), 6.87 (d, J = 4.8 Hz, 1H, 6’-H), 7.14 (apparent t, J = 8 Hz, 1H, 5-H), 7.58 (d, J = 5.6 Hz,
1
3
H, HetArH), 8.14 (d, J = 5.6 Hz, 1H, HetArH), 8.49 (d, J = 4.8 Hz, 1H, 5’-H) ppm. C MNR
(
DMSO-d
6
, 100.6 MHz): δ 115.2 (CH), 116.0 (6’-CH), 118.7 (2-CH), 121.0 (CH), 125.0 (CH),
128.1 (C), 130.3 (C), 130.5 (5-CH), 131.8 (CH), 142.8 (C), 147.4 (5’-CH), 150.3 (C), 155.7 (C)
+
ppm. MS (ESI- TOF) m/z (%): 259.03 (M +H, 100). HRMS (ESI-TOF): calcd for C13
H
11
2
N S
2
24

+
[
M +H] 259.0358, found 259.0358. Anal. Cald. for C13
; found 60.57, H 4.01, N 11.02, S 24.42%.
.1.1.3. 4-(Thieno[3,2-b]pyridin-7-ylthio)aniline (2c): Compound 1 (150mg, 0.880mmol) and 4-
H
10
N
2
S : C 60.43, H 3.90, N 10.84, S 24.82
2
%
4
aminothiophenol (110 mg) was treated according to the general procedure. Column chromatography
using 40% ether/petroleum ether gave compound 2c as a yellow solid (210 mg, 90%). Mp 215-216
1
ºC. H NMR (CDCl
3
, 400 MHz): δ 3.85 (br s, 2H, NH ), 6.70 (d, J = 5.2 Hz, 1H, 6’-H), 6.76 (d, J =
2
8.4 Hz, 2H, 2 and 6-H), 7.40 (d, J = 8.4 Hz, 2H, 3 and 5-H), 7.64 (d, J = 5.6 Hz, 1H, HetArH), 7.78
1
3
(
d, J = 5.6 Hz, 1H, HetArH), 8.39 (d, J = 5.2 Hz, 1H, 5’-H) ppm. C NMR (CDCl
3
,100.6 MHz): δ
114.5 (6 ‘-CH), 116.0 (2 and 6-CH), 124.2 (CH), 130.2 (C), 131.1 (CH), 135.8 (C), 136.4 (C), 137.4
+
(
3 and 5-CH), 145.2 (5’-CH), 148.7 (C), 153.6 (C) ppm. MS (EI- TOF) m/z (%): 258.03 (M , 100).
+
HRMS (EI-TOF): calcd for C13
H
10
N
2
S
2
[M ] 258.0285, found 258.0289. Anal. Cald. for
C
13
H
10
N
2
S
2
: C 60.43, H 3.90, N 10.84, S 24.82 %; found 60.59, H 4.11, N 10.90, S 24.40%.
.1.2. General procedure for the synthesis of 1,3-diarylureas 3-5: Compounds 2a-c and different
arylisocyanates (1equiv.) in 6 mL CH Cl : THF (1:1) were left stirring at room temperature for 12 h.
4
2
2
If a precipitate does not come out after this time, hexane (3-5 mL) was added to the mixture to
precipitate the product. This was filtered under vacuum to give the corresponding 1,3-diarylureas.
4.1.2.1. 1-Phenyl-3-[2-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (3a): From compound 2a (100
mg, 0.390 mmol) and phenylisocyanate (50.0 mg) compound 3a was isolated as a green solid (95.0
1
mg, 65%). Mp 198-199 ºC. H NMR (DMSO-d
6
, 300MHz): δ 6.56 (d, 1H, J = 4.8 Hz), 6.92-6.98
(
m, 1H), 7.12-7.18 (m, 1H), 7.24-7.29 (m, 2H), 7.37-7.46 (m, 2H), 7.54-7.63 (m, 3H), 8.18 (d, 1H, J
=
5.6 Hz), 8.28-8.31 (m, 1H), 8.45 (d, 1H, J = 4.8 Hz), 8.49 (br s, 1H, NH), 9.36 (br s, 1H, NH)
1
3
ppm. C NMR (DMSO-d
6
, 75.4MHz): δ 114.3 (CH), 115.3 (C), 118.2 (CH), 118.3 (2×CH), 121.3
(CH), 122.1 (CH), 123.6 (CH), 125.0 (CH), 128.8 (2×CH), 129.5 (C), 131.9 (CH), 137.3 (CH),
139.3 (C), 142.3 (C), 142.4 (C), 147.5 (CH), 152.2 (C), 155.8 (C) ppm. MS (ESI- TOF) m/z (%):
25

+
+
3
78.07 (M +H, 100) HRMS (ESI-TOF): calcd for C20
Anal. Cald. for C20 OS : C 63.64, H 4.01, N 11.13, S 16.99%; found C 63.83, H 4.13, N 10.83,
S 16.60%.
.1.2.2. From
H
16
N
3
OS
2
[M +H] 378.0729, found 378.0723.
H
15
N
3
2
4
1-(4-Methoxyphenyl)-3-[2-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea
(3b):
compound 2a (100 mg, 0.390 mmol) and 4-methoxyphenylisocyanate (83.0 mg), compound 3b was
1
isolated as a green solid (100 mg, 63%). Mp 198-199 ºC. H NMR (DMSO-d
6
, 400 MHz): δ 3.68 (s,
3
7
8
H, OMe), 6.55 (d, J = 5.2 Hz, 1H), 6.82 (d, J = 9.2 Hz, 2H), 7.13 (m, 1H), 7.28 (d, J = 9.2 Hz, 2H),
.53-7.61 (m, 3H), 8.18 (d, J = 5.6 Hz, 1H), 8.31 (dd, J = 8.4 and 1.2 Hz, 1H), 8.38 (br s, 1H, NH),
1
3
.45 (d, J = 5.2 Hz, 1H), 9.17 (br s, 1H, NH) ppm. C NMR (DMSO-d
6
,100.6 MHz): δ 55.1 (OMe),
114.0 (2xCH), 114.2 (CH), 114.9 (C), 120.1 (2xCH), 121.0 (CH), 123.3 (CH), 125.0 (CH), 129.4
(
C), 131.8 (CH), 131.9 (CH), 132.2 (C), 137.2 (CH), 142.3 (C), 142.5 (C), 147.5 (CH), 152.3 (C),
+
1
54.6 (C), 155.8 (C) ppm. MS (ESI- TOF) m/z (%): 408.08 (M +H, 100). HRMS (ESI-TOF): calcd
+
for C21
H
18
N
3
O
2
S
2
[M +H] 408.0835, found 408.0832. Anal. Cald. for C21
H
17
N
3
O
2
2
S : C 61.89, H
4
4
2
.20, N 10.31, S 15.74%; found C 62.01, H 4.05, N 11.00, S 15.33%.
.1.2.3. 1-(4-Cyanophenyl)-3-[2-(thieno[3,2-b]piridin-7-ylthio)phenyl]urea (3c): From compound
a (60.0 mg, 0.230 mmol) and 4-cyanophenylisocyanate (37.0 mg) compound 3c was isolated as a
1
green solid (60.0 mg, 65%). Mp 208-209 ºC. H NMR (DMSO-d
6
, 300 MHz): δ 6.57 (d, J = 5.2 Hz,
1H), 7.17-7.22 (m, 1H), 7.58-7.60 (m, 5H), 7.68 (d, J = 9.2 Hz, 2H), 8.17 (d, J = 5.6 Hz, 1H), 8.24
(
dd, J = 8.4 and 1.5 Hz, 1H), 8.45 (d, J = 5.2 Hz, 1H), 8.65 (br s, 1H, NH), 9.80 (br s, 1H, NH) ppm.
1
3
C NMR (DMSO-d , 75.4 MHz): δ 103.6 (C), 114.5 (CH), 116.3 (C), 118.1 (2xCH), 119.2 (C),
6
121.7 (CH), 124.3 (CH), 125.0 (CH), 129.6 (C), 131.9 (CH), 131.9 (CH), 133.3 (2xCH), 137.2
(
(
CH), 141.7 (C), 142.1 (C), 143.8 (C), 147.5 (CH), 151.9 (C), 155.8 (C) ppm. MS (ESI- TOF) m/z
+
+
%): 403.07 (M +H, 100). HRMS (ESI-TOF): calcd for C21
H
15
N
4
OS [M +H] 403.0682, found
2
4
03.0689. Anal. Cald. for C21 OS : C 62.67, H 3.51, N 13.92, S 15.93%; found C 62.95, H
H
14
N
4
2
26

3.32, N 14.12, S 15.51%.
4
.1.2.4. 1-Phenyl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (4a): From compound 2b (80.0
mg, 0.300 mmol) and phenylisocyanate (36.0mg) compound 4a was isolated as a yellow solid
1
(
(
70mg, 63%). Mp 94-95 ºC. H NMR (DMSO-d
6
, 400 MHz): δ 6.95 (d, J = 5.2 Hz, 1H), 6.96-6.98
m, 1H), 7.17-7.20 (m, 1H), 7.24-7.28 (m, 2H), 7.39-7.44 (m, 3H), 7.49-7.52 (m, 1H), 7.60 (d, J =
.6 Hz, 1H), 7.78-7.79 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.70 (br s, 1H,
5
1
3
NH), 8.90 (br s, 1H, NH) ppm. C NMR (DMSO-d
6
, 100.6 MHz): δ 116.5 (CH), 118.4 (2xCH),
119.3 (CH), 122.1 (CH), 122.8 (CH), 125.0 (CH), 127.0 (CH), 128.7 (2xCH), 128.8 (C), 130.5
(
CH), 130.8 (C), 132.0 (CH), 139.4 (C), 141.2 (C), 141.9 (C), 147.6 (CH), 152.4 (C), 155.9 (C)
+
ppm. MS (ESI- TOF) m/z (%): 378.07 (M +H, 100) HRMS (ESI-TOF): calcd for C20
H
16
N
3
OS
2
+
[
M +H] 378.0729, found 378.0728. Anal. Cald. for C20
H
15
N
3
OS : C 63.64, H 4.01, N 11.13, S
2
16.99%; found C 63.86, H 3.80, N 11.33, S 16.59%.
4.1.2.5. 1-(4-Methoxyphenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea
(4b):
From
compound 2b (100 mg, 0.390 mmol) and 4-methoxyphenylisocyanate (58.0 mg), compound 4b was
1
isolated as a yellow solid (100 mg, 64%). Mp 132-133 ºC. H NMR (DMSO-d
6
, 400 MHz): δ 3.69
(
s, 3H, OMe), 6.84 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 4.8 Hz, 1H), 7.16-7.18 (m, 1H), 7.31 (d, J = 8.8
Hz, 2H), 7.30-7.33 (m, 1H), 7.48-7.51 (m, 1H), 7.60 (d, J = 5.6 Hz, 1H), 7.77-7.78 (m, 1H), 8.16 (d,
1
3
J = 5.6 Hz, 1H), 8.50 (br s, 1H, NH), 8.52 (d, J = 4.8 Hz, 1H), 8.80 (br s, 1H, NH) ppm. C NMR
DMSO-d , 100.6 MHz): δ 55.1 (OMe), 113.9 (2xCH), 116.5 (CH), 119.2 (CH), 120.3 (2xCH),
22.7 (CH), 125.0 (CH), 126.9 (CH), 128.8 (C), 130.4 (CH), 130.7 (C), 132.0 (CH), 132.3 (C),
41.4 (C), 141.9 (C), 147.6 (CH), 152.6 (C), 154.6 (C), 155.9 (C) ppm. MS (ESI- TOF) m/z (%):
(
6
1
1
4
4
4
+
+
08.08 (M +H, 100). HRMS (ESI-TOF): calcd for C21
H
18
N
3
O
2
S
2
[M +H] 408.0835, found
08.0833. Anal. Cald. for C21
.45, N 10.02, S 15.35%.
H
17
N
3
O S
2 2
: C 61.89, H 4.20, N 10.31, S 15.74%; found C 62.20, H
27

4.1.2.6. 1-(4-Cyanophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (4c): From compound
2b (60.0 mg, 0.230 mmol) and 4-cyanophenylisocyanate (35.0 mg), compound 4c was isolated as a
1
yellow solid (65.0 mg, 65%). Mp 168-169 ºC. H NMR (DMSO-d
6
, 400 MHz): δ 6.95 (d, J = 5.2
Hz, 1H), 7.21-7.24 (m, 1H), 7.42-7.46 (m, 1H), 7.52-7.55 (m, 1H), 7.59 (d, J = 5.6 Hz, 1H), 7.60 (d,
J = 8.8 Hz, 2H), 7.71 (d, J = 8.8 Hz, 2H), 7.76-7.77 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.53 (d, J =
1
3
5
1
1
.2 Hz, 1H), 9.07 (br s, 1H, NH), 9.23 (br s, 1H, NH) ppm. C NMR (DMSO-d , 100.6 MHz): δ
6
03.5 (C), 116.7 (CH), 118.2 (2xCH), 119.2 (C), 119.6 (CH), 123.0 (CH), 125.0 (CH), 127.5 (CH),
29.0 (C), 130.5 (CH), 130.9 (C), 132.0 (CH), 133.2 (2xCH), 140.7 (C), 141.6 (C), 143.9 (C), 147.6
+
(
CH), 152.0 (C), 155.9 (C) ppm. MS (ESI- TOF) m/z (%): 403.07 (M +H, 100) HRMS (ESI-TOF):
+
calcd for C21
H
15
N
4
OS
2
[M +H] 403.0682, found 403.0680. Anal. Cald. for C21
H
14
N
4
OS : C 62.67,
2
H 3.51, N 13.92, S 15.93%; found C 62.37, H 3.80, N 14.13, S 15.52%.
4.1.2.7. 1-(4-Fluorophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio]phenyl)urea (4d): From compound
2b (60.0 mg, 0.230 mmol) and 4-fluorophenylisocyanate (35.0 mg), compound 4d was isolated as a
1
white solid (65.0 mg, 71%). Mp 140-141 ºC. H NMR (DMSO-d
6
, 400 MHz): δ 6.93 (1H, d, J = 5.2
Hz), 7.07-7.12 (m, 2H), 7.18-7.20 (m, 1H), 7.39-7.44 (m, 3H), 7.50-7.52 (m, 1H), 7.60 (d, J= 5.6
Hz, 1H), 7.76-7.77 (m, 1H), 8.16 (d, J = 5.6 Hz, 1H), 8.52 (d, J = 5.2Hz, 1H), 8.73 (br s, 1H, NH),
1
3
8
.89 (br s, 1H, NH) ppm. C NMR (DMSO-d
6
, 100.6 MHz): δ 115.3 (d, J = 22 Hz, 2×CH), 116.6
(CH), 119.4 (CH), 120.2 (d, J = 7.0 Hz, 2×CH), 122.8 (CH), 125.1 (CH), 127.1 (CH), 128.9 (C),
130.5 (CH), 130.8 (C), 132.0 (CH), 135.7 (C), 141.2 (C), 141.9 (C), 147.6 (CH), 152.5 (C), 155.9
+
(
C), 157.5 (d, J = 238 Hz, CF) ppm. MS (ESI- TOF) m/z (%): 396.06 (M +H, 100). HRMS (ESI-
+
TOF): calcd for C20
H15FN
3
OS
2
[M +H] 396.0635, found 396.0634. Anal. Cald. for C20
H14FN
3
OS :
2
C 60.74, H 3.57, N 10.63, S 16.22%; found C 61.01, H 3.28, N 10.35, S 15.81%.
4.1.2.8. 1-(3-Fluorophenyl)-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea (4e): From compound
2b (60.0 mg, 0.230 mmol) and 3-fluorophenylisocyanate (35.0 mg) compound 4e was isolated as a
28

1
white solid (63.0 mg, 69%). Mp 104-105 ºC. H NMR (DMSO-d
6
, 400 MHz,): δ 6.77-6.78 (m, 1H),
.93 (d, 1H, J = 5.2 Hz), 7.09-7.11 (m, 2H), 7.19-7.20 (m, 1H), 7.21-7.29 (m, 1H), 7.41-7.52 (m,
H), 7.53-7.54 (m, 1H), 7.60 (d, 1H, J = 5.6 Hz), 7.7-7.7 (m, 1H,), 8.16 (d, 1H, J = 5.6 Hz), 8.52 (d,
6
2
1
1
1
3
H, J = 5.2 Hz), 8.94 (br s, 1H, NH), 8.96 (br s, 1H, NH) ppm. C NMR (DMSO-d
6
, 100.6 MHz): δ
05.0 (d, J = 26 Hz, CH), 108.4 (d, J = 21 Hz, CH), 114.1 (d, J = 2 Hz, CH), 116.6 (CH), 119.5
(CH), 122.9 (CH), 125.0 (CH), 127.3 (CH), 128.9 (C), 130.3 (d, J = 9.6 Hz, CH), 130.5 (CH), 130.8
(
C), 132.0 (CH), 140.9 (C), 141.3 (d, J = 11.5 Hz, C), 141.8 (C), 147.6 (CH), 152.2 (C), 155.9 (C),
+
1
62.3 (d, J = 240 Hz, CF) ppm. MS (ESI- TOF) m/z (%): 396.06 (M +H, 100). HRMS (ESI-TOF):
+
calcd for C20
H15FN
3
OS
2
[M +H] 396.0635, found 396.0627. Anal. Cald. for C20
H14FN
3
OS : C
2
60.74, H 3.57, N 10.63, S 16.22%; found C 61.03, H 3.33, N 10.30, S 15.82%.
4.1.2.9. 1-[3-(Thieno[3,2-b]pyridin-7-ylthio)phenyl]-3-m-tolylurea (4f): From compound 2b (60.0
mg, 0.230 mmol) and m-tolylisocyanate (35.0 mg) compound 4f was isolated as a white solid (65.0
1
mg, 72%). Mp 157-158 ºC. H NMR (DMSO-d
6
, 400 MHz): δ 2.25 (s, 3H, CH ), 6.77-6.79 (m, 1H),
3
6
1
8
.93 (d, 1H, J = 4.8 Hz), 7.11-7.20 (m, 3H), 7.26-7.29 (m, 1H), 7.39-7.44 (m, 1H), 7.49-7.51 (m,
H), 7.60 (d, 1H, J = 5.6 Hz), 7.79-7.80 (m, 1H), 8.16 (d, 1H, J = 5.6 Hz), 8.52 (d, 1H, J = 4.8Hz),
13
.61 (br s, 1H, NH), 8.87 (br s 1H, NH) ppm. C NMR (DMSO-d6, 100.6 MHz): δ 21.2 (CH
3
),
115.5 (CH), 116.5 (CH), 118.9 (CH), 119.3 (CH), 122.8 (CH), 122.8 (CH), 125.0 (CH), 127.0 (CH),
128.6 (CH), 128.8 (C), 130.5 (CH), 132.0 (CH), 137.9 (C), 139.3 (C), 139.6 (C), 141.2 (C), 141.9
+
(
(
C), 147.6 (CH), 152.3 (C), 155.9 (C) ppm. MS (ESI- TOF) m/z (%): 392.09 (M +H, 100). HRMS
+
ESI-TOF): calcd for C21
OS
.1.2.10. 1-[3-(Trifluoromethyl)phenyl]-3-[3-(thieno[3,2b]pyridin-7-ylthio)phenyl]urea (4g): From
-(thieno[3,2-b]pyridine-7-ylthio)aniline (100 mg, 0.387 mmol) and 3-
H
18
N
3
OS
2
[M +H] 392.0886, found 392.0894. Anal. Cald. for
C
21
H
17
N
3
2
: C 64.42, H 4.38, N 10.73, S 16.38%; found C 64.24, H 4.26, N 11.03, S 15.97%.
4
3
(
trifluoromethyl)phenylisocyanate (72.4 mg, 53.4 µL, 0.387 mmol ) compound 4g was isolated as a
29